Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2019 Aug 2;37(47):6933–6941. doi: 10.1016/j.vaccine.2019.02.040

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2019 The Authors

Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.

PMC Copyright notice

Fig. 6 — Immunogenicity of CHO-rH7 with different N-glycan patterns. (A) purified CHO-rH7, CHO-rH7 (KIF), and CHO-rH7 (KIF + E) protein analysis on SDS-PAGE gels with Coomassie blue staining; (B) MN titers (ID-50) in antisera from mice immunized with 0.2 µg CHO-rH7, CHO-rH7 (KIF), or CHO-rH7 (KIF + E) antigen plus PELC/CpG adjuvant; (C) Survival rate and (D) body weight loss from immunized mice following live virus challenge were monitored for 14 days. Mice whose body weights fell below 75% of their initial weights were sacrificed.